ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1102

Impact of COVID-19 Infection in a Glomerular Disease Unit

Session Information

  • COVID-19 - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Uriol Rivera, Miguel, Hospital Universitario Son Espases, Palma, Illes Balears, Spain
  • Ojeda, Felipe Ignacio, Hospital Universitario Son Espases, Palma, Illes Balears, Spain
  • Ródenas, Estela Mas, Hospital Universitario Son Espases, Palma, Illes Balears, Spain
  • Obrador, Aina, Hospital Universitario Son Espases, Palma, Illes Balears, Spain
  • Jimenez, Sonia, Hospital Universitario Son Espases, Palma, Illes Balears, Spain

COVID-19 infection poses a significant global health challenge, yet its impact on glomerular disease patients (GDP) remains understudied. This research aims to investigate the mortality and chronic renal replacement therapy (CRRT) rates among GDP, identify predictive factors, and explore the influence of proteinuria on the evolution of estimated glomerular filtration rate (eGFR).


This retrospective study compares the annual eGFR changes in GDP before and after COVID-19 infection. The study period spans from January 10, 2020, to July 28, 2022. Proteinuria was defined as a urine protein/creatinine ratio exceeding 0.2 mg/mg.


Among the 302 GDP included, 64 (21%) contracted COVID-19. The mean age was 47 years. Sex: Females 31 (48%) patients. Infection rates were 9% in 2020, 28% in 2021, and 63% in 2022. Of the infected patients, 12 (19%) either died (9) or initiated CRRT (3). Age, eGFR, and proteinuria at admission were identified as independent predictive factors for death or the need for chronic renal replacement therapy. Hospitalization was required for 21 (33%) patients, with 6 necessitating intensive care unit admission. Excluding those who died or initiated CRRT, 52 patients were followed up for an average duration of 17 months (ranging from 9 to 40 months). During this period, the annual mean change in eGFR between the pre- and post-COVID-19 infection periods was -10.3 mL/min/1.73m2 (95% confidence interval: -17.9 to -2.8, P=0.008). At the time of infection, eGFR decreased by 6.8 mL/min/1.73m2 (3.9 to 9.8). Patients without proteinuria experienced eGFR recovery, while those with proteinuria exhibited a progressive decline in eGFR (Figure 1).


Twelve (19%) GDP patients either died or initiated CRRT, with age, eGFR, and proteinuria serving as significant predictor factors.
The trajectory of eGFR shifted following COVID-19 infection in GDP, with proteinuria notably contributing to a progressive and accelerated decline in eGFR.